TYRA shows deteriorating financial performance with operating cash flow worsening 36% to -$95.1M and net losses expanding 39% to -$119.9M, driven by a 29% increase in R&D spending.
The company is burning through cash at an accelerated pace while advancing its clinical programs, with total assets declining 22% and cash reserves dropping 16% to $77.4M. While increased R&D spending signals continued investment in pipeline development, the worsening cash flow trajectory raises questions about runway duration and potential future financing needs.
TYRA's financial position shows broad-based deterioration across key metrics, with operating cash outflows increasing 36% to -$95.1M driven primarily by a 29% surge in R&D expenses to $102.9M as the company advances its clinical programs. The company's balance sheet contracted significantly, with total assets declining 22% to $282.6M and stockholders' equity falling 25% to $259.2M, while cash reserves dropped 16% to $77.4M. This financial profile reflects a clinical-stage biotech company investing heavily in development but facing accelerating cash burn that may necessitate future financing.
Capex reduced 78.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Net income declined 38.7% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow fell 36.4% — earnings quality concerns; investigate working capital changes and non-cash items.
R&D investment increased 28.5% — signals commitment to future product development, though near-term margin impact.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Equity decreased 24.5% — buybacks or losses reducing book value, monitor solvency ratios.
Current liabilities rose 24% — increased short-term obligations, watch current ratio.
Current assets declined 23.6% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 22.3% — asset sales, write-downs, or balance sheet optimization underway.
Cash decreased 15.9% — monitor burn rate and upcoming capital needs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →